Drug efficacy and pharmacological action of an organoselenium compound ethaselen, a novel antitumor drug

• Review • Previous Articles Next Articles

Drug efficacy and pharmacological action of an organoselenium compound ethaselen, a novel antitumor drug

Jia-Ning Fu, Jing-Yu Wang, Li-Hui Wang, Lei Wang, Wan-Chen Tang, Gao-Xiong Cai, Mi Liu, Hui-Hui Zeng^*

State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center; Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China

Received:2009-12-17 Revised:2010-03-15 Online:2010-05-15 Published:2010-05-15
Contact: Hui-Hui Zeng*

Abstract

Abstract: Ethaselen, an organoselenium compound designed and synthesized in the School of Pharmaceutical Sciences, Peking University, has been entitled to independent intellectual property rights both at home and abroad. As one of the novel antitumor drugs, ethaselen has been extensively studied in Phase I clinical trial, and its biological target is thioredoxin reductase. In this review, we focus on the ethaselen’s efficacy and pharmacological actions, including antitumor effects both in vitro and in vivo, and immunologic functions. These research findings not only provide the theoretical basis for the anticancer study of ethaselen, but also guide the clinical trial of ethaselen.

Key words: Ethaselen, Organoselenium compounds, Antitumor effect, Immunologic function, Thioredoxin reductase

CLC Number:

R962

Supporting:

Jia-Ning Fu, Jing-Yu Wang, Li-Hui Wang, Lei Wang, Wan-Chen Tang, Gao-Xiong Cai, Mi Liu, Hui-Hui Zeng^* . Drug efficacy and pharmacological action of an organoselenium compound ethaselen, a novel antitumor drug [J]. .

References

[1] El-Bayoumy, K. J. Drugs Fut. 1997, 22, 539-545.
[2] Ip, C.; Lisk, D.J.; Ganther, H.; Thompson, H.J. Anticancer Res. 1997, 17, 3195-3199.
[3] Rao, C.V.; Wang, C.Q. Cancer Res. 2001, 61, 3647-3652.
[4] El-Bayoumy, K.; Narayanan, B.A.; Desai, D.H.; Narayanan, N.K.; Pittman, B.; Amin, S.G.; Schwartz, J.; Nixon, D.W. Carcinogenesis. 2003, 9, 1505-1514.
[5] Shi, C.; Yu, L.Z.; Yang, F.G.; Yan, J.; Zeng, H.H. Biochem. Biophys. Res. Commun. 2003, 309, 578-583.
[6] Zhao, F.; Yan, J.; Deng, S.; Lan, L.; He, F.; Kuang, B.; Zeng, H.H. Cancer Lett. 2006, 236, 46-53.
[7] Xing, F.; Li, S.; Ge, X.; Wang, C.; Zeng, H.H.; Li, D.; Dong, L. Oral Oncol. 2008, 44, 963-969.
[8] Peng, Z.F.; Lan, L.X.; Zhao, F.; Li, J.; Tan, Q.; Yin, H.W.; Zeng, H.H. J. Zhejiang Univ. Sci. B. 2008, 9, 16-21.
[9] Tan, Q.; Li, J.; Yin, H.W.; Wang, L.H.; Tang, W.C.; Zhao, F.; Liu, X.M.; Zeng, H.H. Invest. New Drugs. 2010, 28, 205-215.
[10] Lan, L.X.; Zhao, F.; Wang, Y.; Zeng, H.H. Eur. J. Pharmacol. 2007, 555, 83-92.
[11] Deng, S.J.; Kuang, B.; Zhou, X.; Yan, J.; Zhao, F.; Jia, X.Y.; Zeng, H.H. J. Peking Univ (Health Sci.). 2003, 35, 108-109.
[12] Li, J.; Fang, J.C.; Zeng, H.H. Chin. J. New Drugs Clin. Rem. 2008, 27, 839-843.
[13] Wang, Y.R.; Xiao, J.J.; Dong, X.M.; Meng, S.C.; Deng, S.J.; Kuang, B.; Yan, J.; Zhao, F.; Zeng, H.H. J. Peking Univ (Health Sci.). 2006, 38, 634-639.
[14] Wang, Y.R.; Zeng, H.H. J. Peking Univ (Health Sci.). 2005, 37, 421-424.
[15] Hu, S.K.; Yu, Y.; Zhang, R.J. J. Xi'an Jiaotong Univ (Med. Sci.). 2009, 30, 44-123.
[16] Shi, C.; Zeng, H.H.; Li, H.W. Chin. Med. J. 2003, 83, 1984-1988.
[17] Yan, J.; Deng, S.J.; Kuang, B.; Zeng, H.H. J. Chin. Pharm. Sci. 2004, 13, 199-204.
[18] Arnér, E.S.; Holmgren, A. Semin. Cancer Biol. 2006, 16, 420-426.
[19] Urig, S.; Becker, K. Semin. Cancer Biol. 2006, 16, 452-465.
[20] Orrenius, S. Toxicol. Lett. 2004, 149, 19-23.
[21] Shi, W.X.; Stan, T.; Kenned, Y.L. J. Biol. Chem. 2006, 281, 10715-10726.
[22] Nouri, A.; Bergbaum, A.; Lederer, E. Eur. J. Cancer. 1991, 27, 608-612.
[23] Fatima, R.D.; Jose, A.; Maristela, T. J. Immunol. Methods. 2000, 241, 121-129.
[24] Hussain, R.F.; Nouri, A.; Oliver, R. J. Immunol. Methods. 1993, 160, 89-96.
[25] Chu, Y.J.; Li, X. Guangdong Trace Elem. Sci. 1997, 4, 281-287.
[26] Mitsuhiro, M.; Takayuki, I.; Shigeo, H.; Tadao, U.; Nobuo, I. Leuk. Res. 2009, 33, 119-120.
[27] Ge, W.; Ma, X.T.; Li, X.; Wang, Y.F.; Li, C.H.; Meng, H.X.; Liu, X.F.; Yu, Z.; You, S.G.; Qiu, L.G. Leuk. Res. 2009, 33, 948-957.
[28] Abe, Y.; Muto, M.; Nieda, M.; Nakagawa, Y.; Andrew, N.; Kaneko, T.; Gotod, S.; Yokokawa, K.; Suzuki, K. Exp. Hematol. 2009, 37, 956-968.
[29] Hiroshi, I.; Yutaka, H.; Teppei, N. Vet. Immunol. Immunopathol. 2009, 132, 85-90.
[30] Copier, J.; Dalgleish, A.G.; Britten, C.M. Eur. J. Cancer. 2009, 45, 1424-1431.
[31] Vaios, K.; Sanaa, K.; Theodora, K. Cancer Lett. 2009, 282, 159-166.